Physician profile
Deming Mi
NPI 1275938870
$8,069.17
in general payments reported to CMS, 2019-2025
35 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $1,275 · 2021: $26.90 · 2022: $1,074 · 2023: $1,663 · 2024: $1,702 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,976.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,081.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,028.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $866.14 | 2022-2025 | |
| Amgen INC. | $643.31 | 2020-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $636.08 | 2021-2025 | |
| Lilly USA, LLC | $613.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.25 | 2019-2025 | Jardiance |
| Radius Health, INC. | $468.50 | 2019-2025 | Tymlos |
| Pfizer INC. | $384.61 | 2019-2025 | |
| Gilead Sciences, INC. | $226.93 | 2020-2023 | |
| Exact Sciences Corporation | $218.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $170.53 | 2019-2023 | Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $166.45 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $125.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $112.38 | 2019-2023 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deming Mi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.